Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
J Womens Health (Larchmt). 2023 Sep;32(9):970-981. doi: 10.1089/jwh.2022.0412. Epub 2023 Jun 16.
Underscreened, low-income, and uninsured or publicly insured women in the United States bear a greater burden of cervical cancer morbidity and mortality and may face unique barriers that preclude screening adherence. Participants were 710 My Body My Test-3 clinical trial participants who were publicly insured or uninsured with incomes ≤250% of the U.S. Federal Poverty Level, aged 25-64 years, and not up to date on cervical cancer screening as per national guidelines. Using Health Belief Model constructs, we assessed screening-related knowledge, perceptions, and behaviors-overall and stratified by race and ethnicity-and estimated associations with past-year attempted screening using multivariable regression models. Overall, knowledge was low about the human papillomavirus, purpose of a Pap test, and recommended screening interval. Perceived severity of cervical cancer was high (3.63 on a 4-point scale). Black and Latina/Hispanic women were more likely to perceive screening as lowering their risk of cervical cancer than White women. Black women reported lower perceived risk of cervical cancer compared with White women ( = 0.03), but Black women were more likely to have sought screening in the past year ( = 0.01). Having at least three doctor visits in the past year was associated with a screening attempt. Greater perceived risk of cervical cancer, more positive perceptions of screening, and feeling more nervousness about screening were also associated with a screening attempt (all < 0.05). Addressing knowledge gaps and misconceptions about cervical cancer screening and leveraging positive perceptions of screening may improve screening uptake and adherence among diverse underscreened U.S. women. Clinical Trial Registration Number: NCT02651883.
美国未接受筛查、收入低、没有保险或仅有公共保险的女性,在宫颈癌发病率和死亡率方面承受着更大的负担,并且她们可能面临独特的障碍,导致无法坚持筛查。本研究共纳入 710 名 My Body My Test-3 临床试验参与者,这些参与者为公共保险或无保险人群,收入≤美国联邦贫困线的 250%,年龄在 25-64 岁之间,且未按照国家指南及时进行宫颈癌筛查。我们使用健康信念模型的结构,评估了筛查相关的知识、认知和行为(总体以及按种族和族裔分层),并使用多变量回归模型估计了过去一年尝试筛查与这些因素的相关性。总体而言,参与者对人乳头瘤病毒、巴氏涂片检查的目的和推荐的筛查间隔时间了解较少。参与者认为宫颈癌的严重程度较高(4 分制,得分为 3.63)。与白人女性相比,黑人和拉丁裔/西班牙裔女性更倾向于认为筛查可以降低宫颈癌风险。与白人女性相比,黑人女性报告的宫颈癌风险较低( = 0.03),但过去一年黑人女性更有可能进行筛查( = 0.01)。过去一年至少有 3 次就诊与尝试筛查有关。更高的宫颈癌风险感知、对筛查的更积极认知以及对筛查的更多紧张感,也与尝试筛查相关(均 < 0.05)。解决有关宫颈癌筛查的知识差距和误解,并利用对筛查的积极认知,可能会提高美国不同未筛查女性的筛查参与度和坚持度。临床试验注册号:NCT02651883。